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Liposomal amphotericin B (LAmB) is widely used in the treatment of invasive fungal disease (IFD) in adults and children. There
are relatively limited pharmacokinetic (PK) data to inform optimal dosing in children that achieves systemic drug exposures
comparable to those of adults. Our objective was to describe the pharmacokinetics of LAmB in children aged 1 to 17 years with
suspected or documented IFD. Thirty-five children were treated with LAmB at doses of 2.5 to 10 mg kg1 daily. Samples were
taken at baseline and at 0.5- to 2.0-h intervals for 24 h after receipt of the first dose (n 35 patients) and on the final day of ther-
apy (n 25 patients). LAmBwas measured using high-performance liquid chromatography (HPLC). The relationship between
drug exposure and development of toxicity was explored. An evolution in PK was observed during the course of therapy, result-
ing in a proportion of patients (n 13) having significantly higher maximum serum concentrations (Cmax) and areas under the
concentration-time curve from 0 to 24 h (AUC0–24) later in the course of therapy, without evidence of drug accumulation
(trough plasma concentration accumulation ratio of<1.2). The fit of a 2-compartment model incorporating weight and an expo-
nential decay function describing volume of distribution best described the data. There was a statistically significant relationship
betweenmean AUC0–24 and probability of nephrotoxicity (odds ratio, 2.37; 95% confidence interval, 1.84 to 3.22; P 0.004).
LAmB exhibits nonlinear pharmacokinetics. A third of children appear to experience a time-dependent change in PK, which is
not explained by weight, maturation, or observed clinical factors.
The small unilamellar liposomal formulation of amphotericin B(LAmB; AmBisome) is widely used for the treatment of inva-
sive fungal disease (IFD) in adults and children. This compound
has been available for over 2 decades and is a first-line agent in the
treatment of serious opportunistic diseases that include invasive
aspergillosis, invasive candidiasis, cryptococcal meningoencepha-
litis, and mucormycosis (1–4).
Despite extensive clinical experience, many of the details relat-
ing to the underlying pharmacological properties of LAmB re-
main unclear. A limited number of data sets and population phar-
macokinetic (PK) models have been reported for LAmB (5–7).
These analyses were based on data gathered from patients receiv-
ing relatively low doses and exclusively sampled early in the course
of therapy. There are very limited data reporting the PK of LAmB
in pediatric populations.
A better understanding of the pharmacological properties of
LAmB remains a priority and would enable optimal dosing, par-
ticularly for special populations, such as infants and children.
Doses ranging from 2.5 to 10 mg kg1 per day were studied, and
each patient was intensively sampled. The individual PK profiles
for a subpopulation of participants (n 25) were compared at the
commencement and end of therapy.
MATERIALS AND METHODS
Patients and antifungal regimen. This study was designed as a prospec-
tive, multicenter, open-label phase II clinical trial. Study protocol ap-
proval was obtained from the Ethics Committees of the National Cancer
Institute (Bethesda, MD, USA), Children’s National Medical Center
(Washington, DC, USA), and Georgetown University Medical Center
(Washington, DC, USA). Informed consent was obtained prior to enroll-
ment in each case. A total of 35 children with a diagnosis of confirmed or
suspected IFD were enrolled. Patients received LAmB infused over 1 h at
doses of 2.5, 5.0, 7.5, or 10.0 mg kg1 daily (n  9, 13, 8, and 8, respec-
tively). Two patients received LAmB as treatment for more than one dis-
crete clinical episode requiring antifungal therapy. Patients undergoing
multiple discrete episodes were assigned the same identification number
on each occasion and were handled using the dosing reset function in
Pmetrics.
LAmB (AmBisome; Gilead Sciences, Inc., Foster City, California) was
supplied as a lyophilized powder and stored at 2 to 8°C until use. Powder
(50 mg) was reconstituted with 12.5 ml of sterile water to a concentration
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of 4mg1ml and then further diluted in 5%dextrose. Reconstituted drug
was used within 6 h.
Pharmacokinetic sampling. PK samples were obtained on the first
and last days of therapy. The first day of LAmBadministrationwas defined
as day one. Heparinized whole-blood samples (0.6 to 1ml) were collected
by peripheral intravenous catheter. Samples were obtained prior to ad-
ministration and at 0.5- to 2.0-h intervals for 24 h following the start of
each infusion. A total of 7 to 12 samples were obtained per patient within
each sampling period (total sampling blood volumes of3ml/kg of body
weight within 24 h). Sampling was repeated in 16 patients on the last day
of therapy (12 to 41 days) using the same sampling schedule. Plasma
fractions were separated by centrifugation at 1,500 g for 10 min at 4°C
and stored at80°C until analysis.
Concentrations of LAmB in plasma were determined by a high-per-
formance liquid chromatographic assay (8). Briefly, total active drug and
internal standard, 3-nitrophenol, were extracted in methanol and sepa-
rated by reversed-phase chromatography. The separation was performed
isocratically using a Supelcosil ABZPlus analytical column (3-m par-
ticle size; 150 mm by 4.6 mm internal diameter; Supelco, Bellefonte,
Pennsylvania), coupled to a Keystone C18 guard column (3-m particle
size; 7.5 mm by 4.6 mm; Western Analytical, Murrieta, California). The
mobile phase, consisting of 10 mM sodium acetate buffer, including 10
mMEDTA (pH 3.6) and acetonitrile (650:350, vol/vol), was delivered at a
flow rate of 1.0ml/min using a Spectra-Physicsmodel 250 pump (Thermo
Separations, San Jose, California). UV absorbency peaks were detected at
a wavelength of 406 nm using a Waters model 440 UV-visible detector
(Waters Corp., Milford, Massachusetts). Two overlapping standard
curves were used: 0.05 to 20 g/ml and 0.5 to 200 g/ml. The assay was
linear over a range of 0.05 to 20 and 0.5 to 200 g/ml (r2 0.995). Intra-
and interday coefficients of variation were 9.5 and 7.0% as well as 5.4 and
6.0%, respectively, and the limit of quantification was 0.05 g/ml. The
average recovery was 90.5% at the concentrations of quality control sam-
ples with a standard deviation (SD) of 6.2%.
Population pharmacokinetic modeling. For population pharmaco-
kineticmodeling, datawere analyzed using a nonparametricmethodology
within the program Pmetrics (version 1.2.6; University of Southern Cali-
fornia, Los Angeles, CA) (9). The observed data were weighted using the
inverse of the estimated assay variance.
Structural models were constructed and used to fit patient data. One-,
two-, and three-compartmentmodels with zero-order drug input into the
central compartment and both first-order and nonlinear (Michaelis-
Menten) elimination from the central compartment were explored. A
proportion of patients had concentration-time profiles that indicated an
intraindividual change in PK during the course of therapy (n 13; 52%).
Affected individuals demonstrated amarked increase in excursion of drug
concentrations from Cmax to trough plasma concentration (Cmin) and a
disproportionate increase in AUC0–24 (Fig. 1). This change was not asso-
ciated with rising trough concentrations, suggesting the phenomenon did
not result fromdrug accumulation resulting from conventional nonlinear
(Michaelis-Menten) kinetics (accumulation ration [AR] of1.2). Inspec-
tion of the data suggested the clearance of drug was the same in both
sampling periods. Hence, the following structural model that allowed the
volume of distribution (V) to change with time was explored. In this
model, volume contracted with time and was described using an expo-
nential decay function. Clearance (CL) was scaled according to weight
using a standard 0.75 power function. The following differential equa-
tions describe the final model:
X1
t
 R1  CI  wt700.75V  X1
 Kcp  X1  Kpc  X2 (1)
X2
t
 Kcp  X1  Kpc  X2 (2)
V
t
 Vin  K  Vfin (3)
FIG 1 Concentration-time profiles for each patient on day one of therapy
(n  35) and at completion of therapy (n  25). Closed circles are the raw
pharmacokinetic data from each patient.
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where X(1) and X(2) represent the total (bound and free) amount of
LAmB (inmilligrams) in the central (c) and peripheral (p) compartments,
respectively. R(1), Kcp, and Kpc represent the rate of infusion into the
central compartment (in milligrams per hour) and first-order intercom-
partmental rate constants, respectively. CL is normalized according to
data for a 70-kg individual and allometrically scaled. The volume of the
central compartment (Vc) is described by an exponential decay function
in which initial volume (Vin) reduced over time according to a rate con-
stant to a final volume (Vfin).
The goodness-of-fit of each model to the data was assessed by visual
inspection of the observed-predicted values and following linear regres-
sion of the observed-predicted values both before and after the Bayesian
step. The coefficient of determination (r2) and the slope and intercept of
each regression were calculated. Statistical comparison of models was
based on likelihood ratio, in which twice the likelihood difference was
evaluated against a 	2 distribution with an appropriate number of degrees
of freedom. In addition, predictive performancewas assessed according to
weighted-mean errors (a measure of bias) and bias-adjusted weighted-
mean-squared errors (a measure of precision).
The final selected model was validated using a nonparametric boot-
strap resampling technique. Three hundred bootstrap data sets were con-
structed based on random sampling with replacement using ADAPT 5.
Measures of central tendency and dispersion and the 95% confidence
interval (CI) for each parameter value were calculated and compared with
estimates from original data. The selected structural model was then im-
plemented within the simulation module of ADAPT 5 (10). Bayesian es-
timates of the PK parameters for each patient were used to calculate sim-
ulated peak plasma concentration (Cmax), trough plasma concentration
(Cmin), and area under the concentration time curve over 24 h (AUC0–24)
at defined therapeutic time points.
Potential relationships between measures of drug exposure (Cmax,
Cmin, absolute LAmB dosage, weight-adjusted dosage, AUC0–24, and
mean AUC0–24) and toxicity were explored. Toxicity was defined as
changes from baseline values at commencement of therapy with the fol-
lowing parameters: nephrotoxicity as an increase in serum creatinine
(SCr) of0.5mg/dl or doubling of baseline value, hypokalemia as a fall in
potassium of 3.0 mmol/liter or 50% from baseline, anemia as a he-
moglobin of 8.0 g/dl, and hepatotoxicity as a rise in bilirubin by 1.5
mg/dl or aspartate transaminase or alanine aminotransfersase 3 times
above baseline. A conservative definition was used to define changes in
biological parameters in order to overcome variability in sampling be-
tween patients; the pretreatment value was subtracted from the highest
measurement observed for each patient during the treatment course.
RESULTS
The patient demographics of the study cohort are summarized in
Table 1. Themean
 SDweight was 26.9
 14.0 kg with a range of
8.8 to 67.5 kg. There was wide variability in the duration of ther-
apy: the mean
 SD was 11.9
 9.41 days of therapy with a range
of 1 to 41 days. The most common underlying diagnosis was he-
matological malignancy (n  21). Nine patients had undergone
allogeneic hematopoietic stem cell transplantation (HSCT), and
23 received concomitant antineoplastic chemotherapy. The ma-
jority of patients received LAmB as empirical therapy for sus-
pected invasive fungal infection (IFI) (n  31). Seven patients
TABLE 1 Patient demographics of cohorts undergoing sampling on day one of therapy and at steady state
Demographic
Value(s)
Day one (n 35) Steady state (n 25)
Age (mean
 SD, range; yr) 8.7
 4.6 (1–17) 10.5
 6.6 (1–17)
Gender (male:female) 22:13 15:10
Weight (mean
 SD, range; kg) 26.9
 14.0 (8.8–67.5) 25.4
 16.2 (11.2–67.5)
Duration of therapy (mean
 SD, range; days) 11.9
 19.4 (1–41) 15.5
 11.3 (9.5–41)
Underlying diagnosis (no. of patients)
Hematopoietic stem cell transplant
Leukemia 6 5
Sickle cell disease 1 1
Aplastic anemia 1 0
Chemotherapy
Leukemia 8 5
Lymphoma 7 5
Solid tumor 7 4
HIV 4 4
Chronic granulomatous disease 1 1
Clinical syndrome (no. of patients)
Established infection 6 6
Empirical treatment 29 19
Pathogen (no. of patients)
Candida albicans 2 2
Candida parapsilosis 1 1
Aspergillus fumigatus 3 3
Cryptosporidium 1 1
Clinical response (no. of patients)
Success 29 21
Failure 8 4
Breakthrough 1 0
Lestner et al.
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received treatment for confirmed IFI. There were two cases of
invasive aspergillosis due to Aspergillus fumigatus and a further
case that developed during treatment with LAmB that was classi-
fied as a breakthrough infection. Three patients had invasive can-
didiasis: one central-line infection and one severe oesophagitis
due to Candida albicans and one case of candidemia caused by
Candida parapsilosis. There was a single case of cryptococcal me-
ningoencephalitis complicating HIV infection. Clinical success
was defined according to clinical, radiological, and mycological
responses during the study period plus relapse-free survival at 2
months after the end of therapy. Clinical success was reported in
76% of probable (n  29) and 43% (n  3) of proven fungal
infections.
The Bayesian estimates for clearance obtained from standard
two-compartment models for each patient were plotted against
weight. A relationship between the log10-transformed estimates
was apparent. The performance of models incorporating an allo-
metric power function was therefore investigated using a scaling
exponent fixed at 0.75. No significant relationship was found be-
tween Bayesian estimates for volume of distribution (V) and
weight. Differences in clinical factors that might be predicted to
alter the PK of LAmB were explored. No significant differences
were identified in liver function, serum albumin, white blood cell
(WBC) count, total protein concentrations, and use of parenteral
nutrition and concomitant steroids. A relatively poor fit of stan-
dard model structures was apparent (for example, the perfor-
mance of a standard two-compartment model) (Fig. 2). Conven-
tional compartmental model structures failed to account for the
widening excursion of drug concentrations observed in a portion
of patients. The parameter estimates for the base and final model
are summarized in Table 2. The fit of the selected model incorpo-
rating a function describing contraction in V was satisfactory
(r2 0.90) and compared favorably to a standard 2-compartment
model. The final model consisted of eight support points. Mea-
FIG 2 Scatter plots showing observed versus predicted values for population pharmacokinetic models after the Bayesian step with a standard 2-compartment
model (A) and selected model (B). Open circles, dashed lines, and solid lines represent individual observed-predicted data points, line of identity, and the linear
regression of observed-predicted values, respectively.
TABLE 2 Parameter estimates for the final 2-compartment pharmacokinetic model
Parameter and modela Vin (liter) Vfin (liter) Kcp (h
1) Kpc (h1) K (h1) CL (liter h1 70 kg1)
Base
Mean 4.543 NAb 0.28 0.888 NA 0.488
Median 4.095 NA 0.184 0.254 NA 0.545
SD 3.44 NA 0.252 0.387 NA 0.29
Error (CV) 75.72 NA 90.025 43.581 NA 59.426
Selected
Mean 10.654 2.326 0.21 0.057 0.303 0.67
Median 7.998 2.986 0.178 0.033 0.027 0.665
SD 1.523 0.978 0.130 0.01 0.094 0.239
Error (CV) 14.295 42.064 61.905 17.544 31.023 35.672
a CV, coefficient of variation.
b NA, not applicable.
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sures of bias and precision were acceptable (Fig. 2). The bootstrap
mean and 95%CI values for parameters closely approximated the
estimates obtained from the final model (Table 3), indicating that
the parameter estimates from the final model were robust. Both
the mean and median parameter values resulted in comparable
intercepts, slopes, and overall r2 values. The log-likelihood value
for the final model was significantly better (more positive) than
for the standard 2-compartment model (	2  48.95; P value
of0.001). Figure 3 shows the simulated concentration-time pro-
files and rawdata for two examples of patients that exhibited time-
dependent and time-independent changes in PK profiles.
Dose-exposure relationships were further explored. No correla-
tion between absolute dose and exposure (Cmax, Cmin, or AUC0–24)
was observed, an expected finding given the significant variability
in weight within the study population. Significant relationships
between dose per unit of weight and exposure were observed.
Plots of dose-normalized Cmax and AUC0–24 suggest nonlinearity
(Fig. 4), although a dosing threshold associated with a discrete
change in exposure was not observed.
Transient renal impairment and hypokalemia were common,
occurring in 46% (n  16) and 23% (n  8) of patients, respec-
tively. A significant correlation between steady-state exposure
(AUC0–24) and change in serum creatinine (SCr) was observed
(r 0.594, P 0.015) (Fig. 5). A statistically significant relation-
ship existed betweenmeanAUC0–24 and probability of developing
nephrotoxicity (odds ratio, 2.37; 95%CI, 1.84 to 3.22; P 0.004).
There was insufficient clinical information to explore the impact
of other potential determinants of renal impairment (for example,
disease severity and concomitant nephrotoxic drugs) in this study
cohort. No significant correlations were found between LAmB ex-
posure (in terms of absolute dose, weight-adjusted dose, AUC0–24,
or mean AUC0–24) and other toxicity measures, including hypo-
kalemia, anemia, and hepatotoxicity.
TABLE 3 Bootstrap estimates of the selected pharmacokinetic model
Parameter
Bootstrap Final model
Mean estimate 95% CI Mean estimate 95% CI
Vin (liter) 10.677 10.646–10.87 10.654 10.67–10.87
Vfin (liter) 2.345 2.181–3.023 2.326 2.162–3.01
Kcp (h1) 0.311 0.127–0.42 0.210 0.108–0.388
Kpc (h1) 0.057 0.043–0.061 0.057 0.043–0.061
K (h1) 0.303 0.21–0.355 0.302 0.21–0.351
CL (liter h1 70 kg1) 0.675 0.555–0.781 0.670 0.548–0.797
FIG 3 Concentration-time profiles for two patients receiving LAmB (10 mg
kg1). Initial (Vin) and final (Vfin) estimates for volume of distribution (V) are
shown. Open circles and solid lines represent the raw data and simulated
concentration-time profiles for each patient, respectively. Patient A exhibits
evolving PK with a contraction in the V, while patient B exhibits stable V.
FIG 4 Comparisons of dose-normalized Cmax (A) and AUC0–24 (B) at steady
state with respect to dose per unit of weight. Solid and dashed lines represent
linear regression and 95% confidence intervals, respectively.
Lestner et al.
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DISCUSSION
Liposomal amphotericin B is used extensively for the treatment of
IFD. Doses of 3 to 6 mg kg1 are approved in the U.S and the
European Union in both adults and children. These doses are not
based on an in-depth knowledge of the pharmacology of the drug
but rather result from preclinical in vivo studies and clinical trials
that have attempted to identify regimens that appear safe and
effective. There continues to be considerable uncertainty regard-
ing the lowest effective dose of LAmB that achieves adequate an-
tifungal effect. As a result, doses of 1 to 15 mg kg1 have been
studied in a range of clinical settings, including empirical therapy,
invasive aspergillosis, invasive candidiasis, and cryptococcal me-
ningoencephalitis (11–14).
Phase I/II clinical studies of LAmB in children and adults have
highlighted variable, dose-dependent PK. Children and adults re-
ceiving LAmB at conservative daily doses of 1 to 3mg kg1 exhibit
linear PK that are described by standard two- or three-compart-
ment models with first-order elimination (5, 6, 7). Limited data
suggest nonlinearity at higher doses. Walsh et al. observed time-
dependent nonlinear PK and an apparent paradoxical dose-de-
pendent exposure plateau in adults receiving daily doses of 7.5 to
15 mg kg1 (3). The data from pediatric patients in this study
similarly suggests that a proportion of patients exhibit time-de-
pendent nonlinear PK. When the concentration-time profiles of
patients exhibiting nonlinear PK are examined, a significant ex-
cursion in Cmin-Cmin is observed, a change not associated with a
proportional increase in half-life that would be expectedwith clas-
sical nonlinear (Michaelis-Menten) clearance but rather appears
to reflect a contraction in the volume of distribution during the
course of therapy. Whereas the limited data from adults has sug-
gested a paradoxical dose-dependent reduction in exposure at
doses of 7.5 mg kg1, in children higher doses appear to be
associated with an increased probability of nonlinearity. The rea-
son for this difference is unclear and warrants further study.
High-density lipoprotein (HDL)-mediated opsonization of
lipid formulations of amphotericin B within plasma has been
shown to drive uptake into mononuclear phagocytes and deposi-
tion within the liver and spleen (15–18). Hong et al. reported a
negative correlation between Bayesian estimates of volume of dis-
tribution and the fraction ofHDL-associated LAmB in 21 children
and adolescents receiving LAmB at daily doses of 0.8 to 6mg kg1.
We hypothesize that variable HDL saturation and/or phagocyte
uptake are the pathophysiological processes driving the interindi-
vidual variability observed in this study. However, many patients
in this small clinical cohort exhibited significant fluctuations in
hematological parameters such as WBC count over the course of
antifungal therapy, primarily due to underlying hemato-oncolog-
ical diagnoses, and we were not able to further characterize rela-
tionships between specific hematological parameters and volume
contraction. Other significant data, such as plasma HDL concen-
trations, were not quantified in this study. This is an interesting
hypothesis that warrants further study in experimental models
and/or as part of larger clinical trials. LAmB is generally well tol-
erated with a significantly improved toxicity profile compared to
conventional amphotericin B deoxycholate (14). Doses of LAmB
as high as 15 mg kg1 daily have been reportedly well tolerated in
adults (3). A number of studies, including one large randomized
control trial, have, however, described dose-dependent toxicity
with significantly higher rates of renal impairment and hypokale-
mia at doses at or above 10 mg kg1 daily (1). In this study, a
significant proportion of patients developed transient renal im-
pairment and/or hypokalemia during the course of treatment. In
view of the limited data available, significant interindividual vari-
ability, and lack of obvious inflection point in this relationship,
further analysis to define exposure thresholds was not possible.
The correlation between drug exposure and SCr observed here
suggests, however, that clinical vigilance and assiduous monitor-
ing of renal function is required to minimize the probability of
toxicity associated with LAmB.
Taken together, these data suggest that a significant proportion
of pediatric patients receiving LAmB at daily doses of 5.0 mg
kg1 exhibit nonlinear PK with significantly higher peak concen-
trations and overall drug exposure. This phenomenon was not
predicted by clinical covariates quantified in this study. Therapeu-
tic drug monitoring (TDM) thus is likely to be of value in identi-
fying this subpopulation in order to prevent toxicity. Effective
implementation of TDM would require a more detailed under-
stand of exposure-toxicity relationships and data describing dis-
ease severity in children with proven or probable IFD in order to
define target exposure thresholds.
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